alexa Review of the rebound phenomenon in new anticoagulant treatments.
Orthopaedics

Orthopaedics

Orthopedic & Muscular System: Current Research

Author(s): Hermans C, Claeys D

Abstract Share this page

Abstract BACKGROUND: The launch of new anticoagulant treatments has sparked debate as to the optimal drug to use for primary prevention of venous thromboembolism (VTE) in major orthopaedic surgery, for the treatment of VTE, and for stroke prevention in atrial fibrillation, taking into account both efficacy and tolerability. Newer drugs such as fondaparinux and ximelagatran have shown improvements in short-term efficacy or convenience, but such effects may be offset by reduced tolerability. They also raise the question of a possible delayed increase in thromboembolic events after these drugs are stopped, the so-called 'rebound effect'. OBJECTIVE: To review pharmacological and clinical data describing the rebound effect associated with new and standard anticoagulant drugs. RESEARCH DESIGN AND METHODS: Computerized searches, covering the period 1960-2005 for the historical background and physiopathology review, and from 1999 to 2005 for the clinical trial analysis, were performed on BIOSIS, PubMed and clinicaltrials.gov databases. The terms 'rebound', 'anticoagulant', and 'heparin' were used. Only articles written in English were reviewed. Articles with drug interactions from other therapeutic classes or types of vascular surgery and commentary articles were excluded. RESULTS: Available data in relation to a possible rebound phenomenon following cessation of active treatment are very limited. Results coming mainly from orthopaedic surgery trials suggest an increased rate of venous or arterial thromboembolic events with newer anticoagulants, compared with standard anticoagulant therapy. An increase in the rate of serious arterial adverse events has, for example, been observed in VTE patients treated with ximelagatran relative to those receiving warfarin/placebo (short-term exposure: 0.75\% vs 0.26\%, p < 0.05; long-term exposure: 1.70\% vs 0.70\%, p
  • DOI: 10.1185/030079906X89801
  • This article was published in Curr Med Res Opin and referenced in Orthopedic & Muscular System: Current Research

    Relevant Expert PPTs

    Relevant Speaker PPTs

    Recommended Conferences

    Peer Reviewed Journals
     
    Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
    International Conferences 2017-18
     
    Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

    Contact Us

    Agri, Food, Aqua and Veterinary Science Journals

    Dr. Krish

    [email protected]

    1-702-714-7001 Extn: 9040

    Clinical and Biochemistry Journals

    Datta A

    [email protected]

    1-702-714-7001Extn: 9037

    Business & Management Journals

    Ronald

    [email protected]

    1-702-714-7001Extn: 9042

    Chemical Engineering and Chemistry Journals

    Gabriel Shaw

    [email protected]

    1-702-714-7001 Extn: 9040

    Earth & Environmental Sciences

    Katie Wilson

    [email protected]

    1-702-714-7001Extn: 9042

    Engineering Journals

    James Franklin

    [email protected]

    1-702-714-7001Extn: 9042

    General Science and Health care Journals

    Andrea Jason

    [email protected]

    1-702-714-7001Extn: 9043

    Genetics and Molecular Biology Journals

    Anna Melissa

    [email protected]

    1-702-714-7001 Extn: 9006

    Immunology & Microbiology Journals

    David Gorantl

    [email protected]

    1-702-714-7001Extn: 9014

    Informatics Journals

    Stephanie Skinner

    [email protected]

    1-702-714-7001Extn: 9039

    Material Sciences Journals

    Rachle Green

    [email protected]

    1-702-714-7001Extn: 9039

    Mathematics and Physics Journals

    Jim Willison

    [email protected]

    1-702-714-7001 Extn: 9042

    Medical Journals

    Nimmi Anna

    [email protected]

    1-702-714-7001 Extn: 9038

    Neuroscience & Psychology Journals

    Nathan T

    [email protected]

    1-702-714-7001Extn: 9041

    Pharmaceutical Sciences Journals

    John Behannon

    [email protected]

    1-702-714-7001Extn: 9007

    Social & Political Science Journals

    Steve Harry

    [email protected]

    1-702-714-7001 Extn: 9042

     
    © 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
    adwords